FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W129780286> ?p ?o ?g. }

• W129780286 endingPage "8" @default.
• W129780286 startingPage "376" @default.
• W129780286 abstract "Ceritinib, also known as LDK-378 or Zykadia (Novartis), is a second generation inhibitor able to specifically target the anaplastic lymphoma kinase (ALK). In the last five years the interest for ALK small inhibitors grew rapidly, mainly because it was discovered that a small but significant percentage of non-small cell lung cancer (NSCLC) patients carries the oncogenic fusion protein EML4-ALK, in addition to about half percent of anaplastic large cell lymphoma (ALCL) patients, an aggressive but definitely rarer non Hodgkin's T cell lymphoma, and other malignancies. Moreover the first ALK inhibitor, crizotinib (Xalkori or PF02341066) was successfully approved for the treatment of late stages or metastatic ALK+ NSCLC, giving a new, safer therapeutic option for those patients. As predicted from previous clinical experience with other kinase inhibitors, crizotinib resistance inevitably occurred, so the clinical availability of new compounds able to overcome crizotinib resistance became a priority. Recently the first clinical data from the phase I trial on ceritinib were published (N Engl J Med 2014;370:1189-97): 59 patients were enrolled in the dose-escalation phase while additional 71 patients were treated in the following expansion phase. For 19 patients relapsed upon crizotinib treatment, ceritinib was used as second line therapy. Collectively, ORR was 58%, 56% for patients who received crizotinib before. Maximum tolerated dose (MTD) was established at 750 mg daily, but more than half patients had to reduce the drug dose because of adverse events. Finally PFS was 7.0 months. Here we discuss the clinical data presented in this article, comparing ceritinib with the first line inhibitor crizotinib and another second generation ALK inhibitor, alectinib (Chugai-Roche)." @default.
• W129780286 created "2016-06-24" @default.
• W129780286 creator A5052775457 @default.
• W129780286 date "2014-12-01" @default.
• W129780286 modified "2023-09-24" @default.
• W129780286 title "Ceritinib as a promising therapy for ALK related diseases." @default.
• W129780286 cites W1997476230 @default.
• W129780286 cites W2113327188 @default.
• W129780286 cites W2125735484 @default.
• W129780286 cites W2134787029 @default.
• W129780286 doi "https://doi.org/10.3978/j.issn.2218-6751.2014.08.09" @default.
• W129780286 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4367665" @default.
• W129780286 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25806325" @default.
• W129780286 hasPublicationYear "2014" @default.
• W129780286 type Work @default.
• W129780286 sameAs 129780286 @default.
• W129780286 citedByCount "3" @default.
• W129780286 countsByYear W1297802862015 @default.
• W129780286 countsByYear W1297802862017 @default.
• W129780286 countsByYear W1297802862021 @default.
• W129780286 crossrefType "journal-article" @default.
• W129780286 hasAuthorship W129780286A5052775457 @default.
• W129780286 hasConcept C117643217 @default.
• W129780286 hasConcept C126322002 @default.
• W129780286 hasConcept C143998085 @default.
• W129780286 hasConcept C197934379 @default.
• W129780286 hasConcept C2776232967 @default.
• W129780286 hasConcept C2776256026 @default.
• W129780286 hasConcept C2778347629 @default.
• W129780286 hasConcept C2779422266 @default.
• W129780286 hasConcept C2779750558 @default.
• W129780286 hasConcept C535046627 @default.
• W129780286 hasConcept C71924100 @default.
• W129780286 hasConceptScore W129780286C117643217 @default.
• W129780286 hasConceptScore W129780286C126322002 @default.
• W129780286 hasConceptScore W129780286C143998085 @default.
• W129780286 hasConceptScore W129780286C197934379 @default.
• W129780286 hasConceptScore W129780286C2776232967 @default.
• W129780286 hasConceptScore W129780286C2776256026 @default.
• W129780286 hasConceptScore W129780286C2778347629 @default.
• W129780286 hasConceptScore W129780286C2779422266 @default.
• W129780286 hasConceptScore W129780286C2779750558 @default.
• W129780286 hasConceptScore W129780286C535046627 @default.
• W129780286 hasConceptScore W129780286C71924100 @default.
• W129780286 hasIssue "6" @default.
• W129780286 hasLocation W1297802861 @default.
• W129780286 hasOpenAccess W129780286 @default.
• W129780286 hasPrimaryLocation W1297802861 @default.
• W129780286 hasRelatedWork W1957032760 @default.
• W129780286 hasRelatedWork W2080538788 @default.
• W129780286 hasRelatedWork W2516942920 @default.
• W129780286 hasRelatedWork W2792437772 @default.
• W129780286 hasRelatedWork W2811310162 @default.
• W129780286 hasRelatedWork W2916503295 @default.
• W129780286 hasRelatedWork W2951367982 @default.
• W129780286 hasRelatedWork W2968328776 @default.
• W129780286 hasRelatedWork W3158045290 @default.
• W129780286 hasRelatedWork W3197633853 @default.
• W129780286 hasVolume "3" @default.
• W129780286 isParatext "false" @default.
• W129780286 isRetracted "false" @default.
• W129780286 magId "129780286" @default.
• W129780286 workType "article" @default.